stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.89
2.43
+5.01%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Free cash flow
MBX Biosciences, Inc.'s free cash flow for fiscal 2025 was −$81.9M, compared with −$55.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$85.2M. Free cash flow has fallen for 3 consecutive fiscal years. MBX Biosciences, Inc. ranks 429th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$81.9M | — |
| FY2024 | −$55.6M | — |
| FY2023 | −$32.1M | — |
| FY2022 | −$23.6M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$23.5M | — |
| Mar 2026 | −$20.6M | — |
| Dec 2025 | −$19.1M | — |
| Sep 2025 | −$21.9M | — |
| 9 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.5M |
| MBX MBX Biosciences, Inc. | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$196.9M |
| XNCR Xencor, Inc. compare | −$208.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)